PharmaShots | Incisive News in 3 Shots

Subscribe Now

ionis

Ionis Highlighted P-III Study (NEURO-TTRansform) Results of Eplontersen for the Treatment of THereditary Transthyretin-Mediated Amyloid Polyneuropathy

Ionis Highlighted P-III Study (NEURO-TTRansform) Results of Eplontersen for the Treatment of THereditary Transthyretin-Mediated Am...

September 29, 2023

Ionis Entered into an Agreement with Roche for Two Novel RNA-Targeted Programs for Alzheimer's and Huntington's disease

Ionis Entered into an Agreement with Roche for Two Novel RNA-Targeted Programs for Alzheimer's and Huntington's disease

September 28, 2023

Ionis Reports P-III Study (Balance) Results of Olezarsen for Familial Chylomicronemia Syndrome

Ionis Reports P-III Study (Balance) Results of Olezarsen for Familial Chylomicronemia Syndrome

September 27, 2023

Ionis Expands its Collaboration with Novartis to Advance Next Generation Program Targeting Lp(a) for Cardiovascular Disease

Ionis Expands its Collaboration with Novartis to Advance Next Generation Program Targeting Lp(a) for Cardiovascular Disease

August 4, 2023

Ionis Reports 85-Week Results from the P-III Study (NEURO-TTRansform) of Eplontersen for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Ionis Reports 85-Week Results from the P-III Study (NEURO-TTRansform) of Eplontersen for Hereditary Transthyretin-Mediated Amyloid...

July 12, 2023

Ionis Reports Two-Year P-II OLE Study Results of Donidalorsen for the Treatment of Hereditary Angioedema

Ionis Reports Two-Year P-II OLE Study Results of Donidalorsen for the Treatment of Hereditary Angioedema

June 1, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us